Inrig Jula — SEC Form 4 filings
SEC reporting owner CIK 1902368. 15 Form 4 filings on record with FilingPulse; latest filed 2026-09-17.
Transaction summary — filings shown
Covers all 15 filings on record, filed 2024-02-02 to 2026-09-17. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 24 legs across 14 filings — 117,814 shares, $5,433,958 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 20.
- Largest priced transaction: sale of 25,390 shares @ $62.02 ($1,574,604) in Travere Therapeutics, Inc., filed 2026-09-17.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Travere Therapeutics, Inc. (TVTX) | EVP, Head of R&D & CMO | 15 | — | 24 legs · 117,814 sh · $5,433,958 | 20 |
Form 4 filings — Inrig Jula
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-17 | 4 | Travere Therapeutics, Inc. (TVTX) | Option exercise (M): 32,395 @ $8.93 · Sale (S): 25,390 @ $62.02 · Sale (S): 17,284 @ $62.62 · Sale (S): 1,600 @ $63.69 · Sale (S): 400 @ $65.31 · Option exercise (M): 32,395 (derivative) @ $0 | EDGAR |
| 2026-06-22 | 4 | Travere Therapeutics, Inc. (TVTX) | Gift (G): 468 @ $0 | EDGAR |
| 2026-05-06 | 4 | Travere Therapeutics, Inc. (TVTX) | Option exercise (M): 20,000 @ $22.40 · Sale (S): 20,000 @ $45 · Option exercise (M): 4,250 @ $0 · Sale (S): 2,174 @ $46.65 · Sale (S): 311 @ $43.95 · Option exercise (M): 20,000 (derivative) @ $0 · +2 more | EDGAR |
| 2026-04-15 | 4 | Travere Therapeutics, Inc. (TVTX) | Grant/award (A): 14,000 @ $0 · Sale (S): 7,215 @ $41.93 · Sale (S): 1,018 @ $42.61 | EDGAR |
| 2026-02-05 | 4 | Travere Therapeutics, Inc. (TVTX) | Sale (S): 1,547 @ $32.11 · Sale (S): 232 @ $32.85 | EDGAR |
| 2026-02-03 | 4 | Travere Therapeutics, Inc. (TVTX) | Grant/award (A): 28,130 @ $0 · Sale (S): 6,956 @ $32.12 · Grant/award (A): 75,000 (derivative) @ $0 | EDGAR |
| 2026-01-07 | 4 | Travere Therapeutics, Inc. (TVTX) | Sale (S): 2,031 @ $40.18 · Sale (S): 445 @ $37.75 | EDGAR |
| 2025-12-29 | 4 | Travere Therapeutics, Inc. (TVTX) | Option exercise (M): 15,000 @ $8.93 · Sale (S): 15,000 @ $42.00 · Option exercise (M): 15,000 (derivative) @ $0 | EDGAR |
| 2025-07-02 | 4 | Travere Therapeutics, Inc. (TVTX) | Sale (S): 815 @ $14.65 | EDGAR |
| 2025-02-12 | 4 | Travere Therapeutics, Inc. (TVTX) | Option exercise (M): 8,000 · Sale (S): 2,568 @ $23.53 · Option exercise (M): 8,000 (derivative) @ $0 | EDGAR |
| 2025-02-04 | 4 | Travere Therapeutics, Inc. (TVTX) | Grant/award (A): 30,000 @ $0 · Sale (S): 4,207 @ $20.12 · Sale (S): 1,066 @ $20.11 · Grant/award (A): 100,000 (derivative) @ $0 | EDGAR |
| 2025-01-06 | 4 | Travere Therapeutics, Inc. (TVTX) | Sale (S): 2,066 @ $19.10 · Sale (S): 440 @ $18.76 | EDGAR |
| 2024-09-10 | 4 | Travere Therapeutics, Inc. (TVTX) | Sale (S): 684 @ $12.98 | EDGAR |
| 2024-09-09 | 4 | Travere Therapeutics, Inc. (TVTX) | Grant/award (A): 6,750 @ $0 · Sale (S): 2,191 @ $11.52 | EDGAR |
| 2024-02-02 | 4 | Travere Therapeutics, Inc. (TVTX) | Grant/award (A): 25,000 @ $0 · Sale (S): 2,174 @ $8.53 · Grant/award (A): 91,000 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1902368 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →